Final results of the randomized phase II DeLOS-II trial: Induction chemotherapy (IC) followed by radiotherapy (R) vs. cetuximab (E) plus IC and R for functional larynx preservation in resectable laryngeal and hypopharyngeal cancer (LHSCC).

Andreas Dietz, Gunnar Wichmann, Michael Flentje, Rudolf Hagen, Oliver Koelbl, Frank Schreiber, Volker Schilling, Georg Maschmeyer, Ursula C. Schroeder, Christian Sittel,

Journal of Clinical Oncology · 2016 · 11 citations · 0 references

Concepts

Abstract

6025 Background: To evaluate the impact of E added throughout IC and R on the rate of two-year functional laryngectomy free survival (fLFS). Methods: Untreated patients (pts) with stage III/IV LHSCC, amenable to resection by total laryngectomy, were randomized to three cycles of IC with TPF (docetaxel and cisplatin 75 mg/m² day 1 and F 750 mg/m²/day on days 1-5) followed by R (69,6Gy) without (arm A) or with (arm B) standard dose of cetuximab for 16 weeks throughout IC and R. In case of non-response after the first IC cycle, salvage laryngectomy was performed. The primary objective was a 2-year fLFS rate above 35% (lower bound of 80%-CI) in the experimental arm. Results: Of180 pts randomized (7.2007-9.2012), 173 fulfilled ITT criteria. Due to 4 therapy related deaths among the first 64 randomized pts, F was omitted from IC in 2.2009 with no further treatment related deaths in the remaining 112 pts. Table 1 summarizes rates of response, laryngectomy, fLFS and OS. The primary objective of an fLFS above 35% was met, however, the control arm also met objectives. 31.8% (arm A) and 22.7% (arm B) of patients did not respond to first cycle IC. Conclusions: IC with TPFE/TPE was feasible and showed a trend towards being more effective compared to TPF/TP in terms of rates of fLFS and OS. The early response rate to IC of 77.3% and the 1 and 2 year fLFS rates of 63.6% and 46.6%, respectively compare very well to previous larynx preservation trials and suggest effective treatment selection and stratification by early response evaluation to IC. Clinical trial information: NCT00508664.Efficacy and outcome data. Arm A TP(F) – > R Arm B TP(F) – > R plus cetuximab OR (95%CI) Localisation: : : Larynx 44 42 Hypopharynx 41 46 TPF 30 31 TP 55 57 ORR* (n = 126) : : TPF 94.7% 80.0% TP 79.1% 94.9% Laryngectomy 25.9% 33.0% fLFS at 6 months 65.9% 77.3% 0.5680 (0.2905-1.1105) fLFS at 1 year 55.3% 63.6% 0.7068 (0.3842-1.3001) fLFS at 2 years 44.7% 46.6% 0.9268 (0.5094-1.6863) OS at 2 years 68.2% 69.3% 0.9508 (0.4997-1.8091) OR: Odds Ratio; *at final examination